The impact of a conjugate pneumococcal vaccine (Prevenar 13) on the epidemiology and aetiology of childhood pneumonia in the North East of England

Trial Profile

The impact of a conjugate pneumococcal vaccine (Prevenar 13) on the epidemiology and aetiology of childhood pneumonia in the North East of England

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Community-acquired pneumonia; Pneumococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2015 Accrual to date is 46% according to the United Kingdom Clinical Research Network record.
    • 17 Nov 2015 Planned number of patients changed from 500 to 180, according to United Kingdom Clinical Research Network record.
    • 13 Nov 2015 Accrual to date is 16% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top